title: Janus kinase inhibition as a potential strategy for the treatment of psoriasis: state of the art and future perspectives.
abstract: Research is focusing the attention on drugs acting on intracellular signaling as a possible strategy for various malignancies and autoimmune disorders, as well as prevention of transplant rejection. In such a context, an intriguing therapeutic target appears to be the signaling pathway mediated by Janus kinases (JAK)/signal transducers and activators of transcription (STAT) protein family. Several companies are developing and evaluating JAK inhibitors for immune-mediated disorders, including psoriasis. Among these drugs, ruxolitinib and especially tofacitinib have reached more advanced phases of clinical and experimental development. This review discusses the potential role of JAK inhibition in the treatment of psoriasis and presents the preliminary data regarding the clinical development of JAK inhibitors in this disease.
authors.affiliation: Department of Biomedical Sciences and Human Oncology, University of Bari, Italy.
authors.forename: N
authors.initials: N
authors.lastname: Cassano
authors.forename: G A
authors.initials: GA
authors.lastname: Vena
mesh_terms: D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D009570:Nitriles; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000201:enzymology; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use
chemical_list: D009570:Nitriles; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; D011758:Pyrroles; C540383:ruxolitinib; C479163:tofacitinib; D053612:Janus Kinases